Ajinomoto Bio-Pharma Services vs FUJIFILM Diosynth Biotechnologies: CDMO Comparison

How does Ajinomoto Bio-Pharma Services compare to FUJIFILM Diosynth Biotechnologies?

As of Oct 2026, Ajinomoto Bio-Pharma Services: no FDA inspections on file, 1 EMA/MHRA GMP certificate. Signal Score 83.5. FUJIFILM Diosynth Biotechnologies: no FDA inspections on file, 35 EMA/MHRA GMP certificates. Signal Score 86.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Ajinomoto Bio-Pharma Services and FUJIFILM Diosynth Biotechnologies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

San Diego, CA · Osaka, JP
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
—
Modalities
Oligonucleotide, Biologics, AAV
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score
87/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
29
MHRA GMP certificates (compliant)
6
Clinical programs (matched)
0
Capacity
Expanding
Modalities
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Key differences

  • FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
  • FUJIFILM Diosynth Biotechnologies has stronger MHRA / UK coverage (6 compliant certificates vs 1).

Across the cross-modality scorecard, FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Ajinomoto Bio-Pharma Services vs FUJIFILM Diosynth Biotechnologies

How does Ajinomoto Bio-Pharma Services compare to FUJIFILM Diosynth Biotechnologies?

On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 84/100 and FUJIFILM Diosynth Biotechnologies is 87/100; European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 35 for FUJIFILM Diosynth Biotechnologies. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

How do Ajinomoto Bio-Pharma Services and FUJIFILM Diosynth Biotechnologies compare on European GMP coverage?

Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

Ajinomoto Bio-Pharma Services carries a Signal Score of 84/100 and FUJIFILM Diosynth Biotechnologies carries 87/100 — essentially tied for FUJIFILM Diosynth Biotechnologies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Ajinomoto Bio-Pharma Services and FUJIFILM Diosynth Biotechnologies for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.